News
Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $727.2, ...
Capital One outlined some of its to-do items as it integrates with Discover, which include long-haul investments in technology, global marketing and risk management.
On Thursday, Truist Securities offered a reaffirmation of their Buy rating and a $46.00 price target for ARAMARK Holdings (NYSE: NYSE:ARMK), signaling confidence in the stock despite its year-to ...
2don MSN
We recently published a list of 10 Best Stocks to Buy According to Billionaire Chris Rokos. In this article, we are going to ...
Chris Rokos is a highly respected British hedge fund manager who co-founded Brevan Howard Asset Management in 2002 before departing to establish his own firm in 2015, Rokos Capital Management, which ...
2d
MT Newswires on MSNO'Reilly Automotive Likely to Benefit From Tariffs as Customers Focus on Repairing Existing Vehicles, Truist SaysO'Reilly Automotive (ORLY) is likely to benefit from tariffs as customers are expected to prefer maintaining or repairing their current vehicles instead of purchasing new ones, Truist Securities said ...
Analysts' ratings for JPMorgan Chase (NYSE:JPM) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ratings ...
"A lot of the buyside was worried that this (forecast) would need to come down amidst softening consumer spend and travel," analysts at Truist Securities wrote in a note. Profit rose 6% to $2.58 ...
Despite high absolute costs, SNFs still remain a relatively cheaper environment for post-acute care," said Truist Securities in a recent research note. Additionally, the Hunt Valley, MD-based REIT ...
Click here for access. * Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Dollar Tree, targeting a price of $84. * Maintaining their stance ...
Could Summit Therapeutics lead in biotech gains?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results